1. Home
  2. EARN vs TLSA Comparison

EARN vs TLSA Comparison

Compare EARN & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$4.81

Market Cap

179.2M

Sector

Real Estate

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.49

Market Cap

164.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EARN
TLSA
Founded
2012
2013
Country
United States
United Kingdom
Employees
160
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.2M
164.1M
IPO Year
2012
2017

Fundamental Metrics

Financial Performance
Metric
EARN
TLSA
Price
$4.81
$1.49
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$5.38
N/A
AVG Volume (30 Days)
402.6K
200.0K
Earning Date
06-16-2026
05-04-2026
Dividend Yield
20.51%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.69
N/A
Revenue Next Year
$19.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.27
$1.14
52 Week High
$6.08
$2.60

Technical Indicators

Market Signals
Indicator
EARN
TLSA
Relative Strength Index (RSI) 53.39 55.53
Support Level $4.54 $1.23
Resistance Level $5.36 $1.54
Average True Range (ATR) 0.09 0.16
MACD -0.01 0.00
Stochastic Oscillator 64.65 35.36

Price Performance

Historical Comparison
EARN
TLSA

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Share on Social Networks: